Results 211 to 220 of about 34,445,663 (284)

Association of glucagon-like peptide-1 receptor agonist use with patient-reported outcomes after lumbar decompression or fusion. [PDF]

N Am Spine Soc J
Parker J, Brennan J, Johnson A, Peterman M, Patton C, Turcotte J.   +5 more
europepmc   +1 more source

A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding, Qing Liu, Qiong Luo, Xiaojun Yao, Xingxing Fan   +4 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes. [PDF]

J Virol
Zhou R, Yue M, Shen Q, Liu N, Chen Y, Wang P, Kim K, Yang R, Chen H, Yuen K-Y, To KK-W, Xu A, Chen Z.   +12 more
europepmc   +1 more source

Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Care home admission often reflects frailty and limited life expectancy, potentially altering the benefit‐harm balance of glucose‐lowering drug (GLD) treatment for type 2 diabetes (T2D). Real‐world data on treatment patterns in this setting remain limited. We examined GLD use for T2D among Danish care home residents.
Hanin Harbi, Reimar W. Thomsen, Carina Lundby, Jacob Volmer Stidsen, Kurt Højlund, Jesper Ryg, Mette Reilev, Anton Pottegård   +7 more
wiley   +1 more source

Association of glucagon-like peptide-1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes. [PDF]

J Diabetes Investig
Yu YT, Lee YC, Fang YW, Hsieh WH, Tsai MH.   +4 more
europepmc   +1 more source

Association Between Baseline Glucagon-like Peptide-1 Receptor Agonist Use and Newly Documented Depression Diagnosis in Adults with Type 2 Diabetes: A Multi-State Medicaid Cohort Study. [PDF]

Healthcare (Basel)
Ndiulor M, Wang H, Neba R, Rasu R, Zhou B, Sambamoorthi U.   +5 more
europepmc   +1 more source

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this randomised, double‐blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 ...
Jun Sung Moon, Kyung Ah Han, Dong‐Lim Kim, Sang Yong Kim, Soo‐Kyung Kim, Bon Jeong Ku, Woo Je Lee, Tae Keun Oh, Ji A Seo, Sang‐Ah Chang, Moon‐Kyu Lee, Kyu Jeung Ahn, Chul Sik Kim, Tae Nyun Kim, Bong‐Soo Cha   +14 more
wiley   +1 more source

Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus? [PDF]

Cureus
Medeiros R, Mendes I.
europepmc   +1 more source

Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment (OPTIC)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the relative importance of attributes driving obesity medication (OM) choice and preferences among individuals with overweight or obesity. Materials and Methods US adults with obesity or overweight and ≥ 1 obesity‐related complication completed an online survey including a discrete‐choice experiment (DCE) in October–November ...
Jaime P. Almandoz, Beverly G. Tchang, Kelley Myers, Andrea Traina, Jigish Bhavsar, Victoria Divino, Cannon Kent, Sara Tadesse Bell   +7 more
wiley   +1 more source